| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $88M | ||
| $82M |
Buys | $477,900 | 1 | 1 |
Sells | $112,377,294 | 95 | 99 |
| Hayden Michael R | director | 1 | $477,900 | 0 | $0 | $477,900 |
| Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | 0 | $0 | 2 | $224,009 | $-224,009 |
| Kordasiewicz Holly B. | EVP, Chief Development Officer | 0 | $0 | 1 | $313,308 | $-313,308 |
| PARSHALL B LYNNE | director | 0 | $0 | 4 | $2M | $-2M |
| LOSCALZO JOSEPH | director | 0 | $0 | 4 | $2.25M | $-2.25M |
| HERMAN JOAN E | director | 0 | $0 | 1 | $2.31M | $-2.31M |
| Schneider Eugene | EVP, Chf Clinical Develop Ofcr | 0 | $0 | 4 | $2.82M | $-2.82M |
| Birchler Brian | EVP, Corp and Development Ops | 0 | $0 | 6 | $3.5M | $-3.5M |
| KLEIN JOSEPH III | director | 0 | $0 | 3 | $3.7M | $-3.7M |
| Diaz Allene M. | director | 0 | $0 | 2 | $4.42M | $-4.42M |
| HOUGEN ELIZABETH L | EVP, Finance & CFO | 0 | $0 | 3 | $4.8M | $-4.8M |
| Baroldi Joseph | EVP, Chief Business Officer | 0 | $0 | 10 | $5.51M | $-5.51M |
| Devers Shannon L. | EVP, Chief Human Resources Ofc | 0 | $0 | 8 | $5.6M | $-5.6M |
| WENDER JOSEPH H | director | 0 | $0 | 6 | $7.05M | $-7.05M |
| Swayze Eric | EVP Research | 0 | $0 | 9 | $7.22M | $-7.22M |
| Geary Richard S | EVP, Chief Development Officer | 0 | $0 | 7 | $11.45M | $-11.45M |
| O'NEIL PATRICK R. | EVP CLO & General Counsel | 0 | $0 | 10 | $11.69M | $-11.69M |
| BENNETT C FRANK | EVP, Chief Scientific Officer | 0 | $0 | 8 | $14.02M | $-14.02M |
| Monia Brett P | Chief Executive Officer | 0 | $0 | 7 | $23.51M | $-23.51M |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Over the last 12 months, insiders at Ionis Pharmaceuticals, Inc. have bought $477,900 and sold $112.38M worth of Ionis Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Ionis Pharmaceuticals, Inc. have bought $329,489 and sold $30.38M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hayden Michael R (director) — $477,900.
The last purchase of 15,000 shares for transaction amount of $477,900 was made by Hayden Michael R (director) on 2025‑05‑01.
| 2026-03-04 | Sale | LOSCALZO JOSEPH | director | 200 0.0001% | $80.00 | $16,000 | -4.08% | |
| 2026-03-04 | Sale | Baroldi Joseph | EVP, Chief Business Officer | 201 0.0001% | $80.00 | $16,080 | -4.08% | |
| 2026-03-03 | Sale | BENNETT C FRANK | EVP, Chief Scientific Officer | 85,089 0.0508% | $79.23 | $6.74M | -4.35% | |
| 2026-03-03 | Sale | LOSCALZO JOSEPH | director | 832 0.0005% | $80.33 | $66,833 | -4.35% | |
| 2026-03-03 | Sale | Devers Shannon L. | EVP, Chief Human Resources Ofc | 20,106 0.012% | $79.40 | $1.6M | -4.35% | |
| 2026-03-03 | Sale | KLEIN JOSEPH III | director | 21,332 0.0128% | $79.51 | $1.7M | -4.35% | |
| 2026-03-03 | Sale | Baroldi Joseph | EVP, Chief Business Officer | 6,220 0.0037% | $79.72 | $495,867 | -4.35% | |
| 2026-03-03 | Sale | Diaz Allene M. | director | 54,878 0.0328% | $79.35 | $4.35M | -4.35% | |
| 2026-02-13 | Sale | Swayze Eric | EVP Research | 15,642 0.0098% | $81.76 | $1.28M | -2.29% | |
| 2026-02-11 | Sale | PARSHALL B LYNNE | director | 5,000 0.003% | $82.72 | $413,589 | -2.18% | |
| 2026-02-06 | Sale | Monia Brett P | Chief Executive Officer | 29,430 0.018% | $85.79 | $2.52M | -3.93% | |
| 2026-02-02 | Sale | BENNETT C FRANK | EVP, Chief Scientific Officer | 36,463 0.0224% | $82.79 | $3.02M | -1.28% | |
| 2026-01-30 | Sale | Monia Brett P | Chief Executive Officer | 62,970 0.0389% | $82.72 | $5.21M | -1.18% | |
| 2026-01-30 | Sale | HOUGEN ELIZABETH L | EVP, Finance & CFO | 6,988 0.0043% | $83.24 | $581,702 | -1.18% | |
| 2026-01-30 | Sale | BENNETT C FRANK | EVP, Chief Scientific Officer | 5,885 0.0036% | $82.95 | $488,141 | -1.18% | |
| 2026-01-30 | Sale | O'NEIL PATRICK R. | EVP CLO & General Counsel | 6,179 0.0039% | $83.53 | $516,154 | -1.18% | |
| 2026-01-30 | Sale | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | 6,179 0.0039% | $83.45 | $515,630 | -1.18% | |
| 2026-01-30 | Sale | Birchler Brian | EVP, Corp and Development Ops | 6,179 0.0038% | $83.03 | $513,048 | -1.18% | |
| 2026-01-30 | Sale | Swayze Eric | EVP Research | 6,179 0.0038% | $82.93 | $512,446 | -1.18% | |
| 2026-01-30 | Sale | Baroldi Joseph | EVP, Chief Business Officer | 5,296 0.0033% | $82.96 | $439,364 | -1.18% |
| Monia Brett P | Chief Executive Officer | 254497 0.1541% | $18.12M | 0 | 63 | |
| HOUGEN ELIZABETH L | EVP, Finance & CFO | 132881 0.0804% | $9.46M | 0 | 37 | |
| BENNETT C FRANK | EVP, Chief Scientific Officer | 80554 0.0488% | $5.73M | 0 | 85 | |
| O'NEIL PATRICK R. | EVP CLO & General Counsel | 71983 0.0436% | $5.12M | 0 | 89 | |
| Schneider Eugene | EVP, Chf Clinical Develop Ofcr | 69702 0.0422% | $4.96M | 0 | 12 | |
| Birchler Brian | EVP, Corp and Development Ops | 66247 0.0401% | $4.72M | 0 | 10 | |
| Geary Richard S | EVP, Chief Development Officer | 59657 0.0361% | $4.25M | 0 | 66 | |
| PARSHALL B LYNNE | director | 56344 0.0341% | $4.01M | 0 | 101 | |
| Hayden Michael R | director | 50219 0.0304% | $3.58M | 2 | 0 | +10.28% |
| HERMAN JOAN E | director | 46086 0.0279% | $3.28M | 0 | 1 | |
| LOSCALZO JOSEPH | director | 36330 0.022% | $2.59M | 0 | 5 | |
| WENDER JOSEPH H | director | 36035 0.0218% | $2.57M | 0 | 20 | |
| Swayze Eric | EVP Research | 32105 0.0194% | $2.29M | 0 | 23 | |
| Devers Shannon L. | EVP, Chief Human Resources Ofc | 22541 0.0136% | $1.6M | 0 | 9 | |
| Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | 16389 0.0099% | $1.17M | 0 | 2 | |
| Kordasiewicz Holly B. | EVP, Chief Development Officer | 14718 0.0089% | $1.05M | 0 | 1 | |
| KLEIN JOSEPH III | director | 11014 0.0067% | $784,086.66 | 9 | 38 | +49.6% |
| Baroldi Joseph | EVP, Chief Business Officer | 4347 0.0026% | $309,462.93 | 0 | 15 | |
| Diaz Allene M. | director | 3811 0.0023% | $271,305.09 | 0 | 4 | |
| GABRIELI CHRISTOPHER | director | 155431 0.0941% | $11.07M | 0 | 19 | |
| BERTHELSEN SPENCER R | director | 147257 0.0891% | $10.48M | 0 | 8 | |
| Cadoret-Manier Onaiza | EVP,Chf GL Pdt Str & Oper Ofc | 35788 0.0217% | $2.55M | 0 | 5 | |
| MUTO FREDERICK T | director | 31683 0.0192% | $2.26M | 0 | 9 | |
| Castleman Breaux | director | 15183 0.0092% | $1.08M | 0 | 1 | |
| COLE DOUGLAS L | Vice President | 9616 0.0058% | $684,563.04 | 0 | 3 | |
| Boyce Sarah | Chief Business Officer | 8931 0.0054% | $635,797.89 | 0 | 3 | |
| Wedel Mark K | VP & Chief Medical Officer | 6603 0.004% | $470,067.57 | 0 | 5 | |
| LUNDSTEDT KAREN S | Vice President | 5407 0.0033% | $384,924.33 | 0 | 4 | |
| BROWN RICHARD K | Vice President | 2348 0.0014% | $167,154.12 | 0 | 11 | |
| CROOKE STANLEY T | Exec Chairman of the Board | 2021 0.0012% | $143,874.99 | 0 | 170 | |
| LEVIN ARTHUR A | Vice President | 1674 0.001% | $119,172.06 | 0 | 13 | |
| LOWENSTAM PATRICIA | Vice President | 603 0.0004% | $42,927.57 | 0 | 8 | |
| ECKER DAVID J | Vice President | 0 0% | $0 | 0 | 21 | |
| REED JOHN C | director | 0 0% | $0 | 0 | 4 | |
| DE HAAN HANS A | VP, Drug Development | 0 0% | $0 | 0 | 1 | |
| Treble Michael J | Vice President, Pres of Ibis | 0 0% | $0 | 0 | 5 |
$961,890,236 | 276 | 22.46% | $18.42B | |
$211,610,344 | 91 | 38.45% | $10.1B | |
$2,765,836 | 72 | 20.00% | $11.25B | |
$11,789,714 | 49 | 14.35% | $30.07B | |
$88,307,390 | 38 | -1.70% | $10.99B | |
$19,233,721 | 36 | 70.14% | $11.06B | |
$13,655,378 | 35 | 17.13% | $23.5B | |
$1,801,511 | 23 | 18.58% | $7.71B | |
$415,090,639 | 19 | -14.04% | $13.46B | |
$143,065,458 | 17 | 8.01% | $18.8B | |
$1,279,017 | 16 | 51.12% | $7.98B | |
$152,272,932 | 16 | -10.78% | $19.56B | |
$627,701,115 | 15 | 145.68% | $12B | |
Ionis Pharmaceuticals, Inc. (IONS) | $284,820 | 10 | 45.67% | $11.76B |
$948,235 | 8 | 15.56% | $7.96B | |
$55,713,031 | 8 | -0.36% | $8.63B | |
$41,376,000 | 4 | -12.07% | $7.86B | |
$40,276,273 | 4 | 34.57% | $20.08B | |
$999,989 | 1 | 262.16% | $20.76B |
| Increased Positions | 281 | +61.49% | 25M | +14.74% |
| Decreased Positions | 191 | -41.79% | 23M | -13.54% |
| New Positions | 112 | New | 4M | New |
| Sold Out Positions | 45 | Sold Out | 4M | Sold Out |
| Total Postitions | 547 | +19.69% | 171M | +1.21% |
| Fmr Llc | $1.89M | 14.62% | 23.69M | +46,048 | +0.2% | 2025-09-30 |
| Vanguard Group Inc | $1.31M | 10.17% | 16.48M | -233,116 | -1.4% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $1.05M | 8.12% | 13.16M | -3M | -18.02% | 2025-09-30 |
| Capital World Investors | $1.01M | 7.85% | 12.72M | +182,540 | +1.46% | 2025-09-30 |
| Blackrock, Inc. | $832,387.00 | 6.45% | 10.45M | -448,997 | -4.12% | 2025-09-30 |
| Wellington Management Group Llp | $524,931.00 | 4.07% | 6.59M | +243,035 | +3.83% | 2025-09-30 |
| Bellevue Group Ag | $497,495.00 | 3.86% | 6.24M | -2M | -20.48% | 2025-09-30 |
| State Street Corp | $349,644.00 | 2.71% | 4.39M | -141,747 | -3.13% | 2025-09-30 |
| Deep Track Capital, Lp | $303,395.00 | 2.35% | 3.81M | -1M | -22.15% | 2025-09-30 |
| Geode Capital Management, Llc | $244,291.00 | 1.89% | 3.07M | +175,194 | +6.06% | 2025-09-30 |